纳尔德美丁可以允许癌症患者使用更高的氧化剂量吗? 一个单一中心的回顾性研究
Shinya Kajiura1,2,3, Shingo Chikaoka2, Yuta Yagi2
1Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama, Japan.
Journal of palliative medicine
|February 17, 2026
概括
纳尔德美丁是一种外围作用的μ-阿片类受体对抗剂 (PAMORA),通过控制阿片类药物诱导的便秘 (OIC),使得癌症患者能够服用更高的氧化剂量. 这表明PAMORA可以减少在癌症疼痛管理期间切换阿片类药物的需要.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 阿片类药物诱导的便秘 (OIC) 是癌症疼痛管理的一个重大挑战,通常需要减少或切换阿片类药物的剂量.
- 从历史上看,OIC的管理涉及到切换到不太有效的阿片类药物,限制疼痛控制.
- 外周作用的μ-阿片类受体对抗剂 (PAMORAs) 提供了一种新的方法来管理OIC而不影响中央止痛.
研究的目的:
- 评估纳尔德美丁,一个PAMORA,是否允许在癌症患者中增加氧化剂量,而不需要与便秘相关的治疗变化.
- 评估最大预定氧化剂量作为OIC成功管理和持续阿片类药物治疗的替代标记.
主要方法:
- 对2017年6月至2018年12月期间开始服用口服氧化的成年癌症患者的回顾性评估.
- 患者被分为两组:A组 (接受纳尔德美丁) 和B组 (不接受纳尔德美丁).
- 主要终点是控制释放型氧化的最大预定每日剂量,不包括救援剂量.
主要成果:
- 接受纳尔德美丁的患者 (40毫克/天) 的中位数最大氧化剂量明显高于未接受纳尔德美丁的患者 (20毫克/天).
- 这一差异是统计学上显著的 (p < 0.0001).
结论:
- 纳尔德美丁在癌症患者中促进了更高的氧化剂量,这表明OIC的有效管理.
- 这些发现表明,PAMORA可以减少因OIC而导致阿片类药物转换的发生率,改善疼痛管理策略.
相关概念视频
Drug Dosing: Obese Patients
279
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
279
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.2K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
806
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
806
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
241
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
241
Drug Dosing: Geriatric Patients
289
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
289
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
282
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
282

